We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

4,100
Open access books available

116,000
International authors and editors

125M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Aging and Neurological Diseases

Marta Kowalska, Michal Owecki, Michal Prendecki, Katarzyna Wize, Joanna Nowakowska, Wojciech Kozubski, Margarita Lianeri and Jolanta Dorszewska

Abstract

Current knowledge indicates that the aging process starts with subclinical changes at the molecular level. These include the accumulation of mutations, telomere attrition, and epigenetic alterations leading to genomic instability. Such defects multiply exponentially over time, resembling a “snowball effect,” and eventually leading to morphological and functional deterioration of the brain, including progressive neuronal loss, reduced levels of neurotransmitters, excessive inflammation, and disrupted integrity of vessels, followed by infarction and microbleeds. Additionally, the decreasing efficiency of DNA repair mechanisms increases the susceptibility to reactive oxygen species and spontaneous mutagenesis, resulting in age-related neoplasia. Moreover, the malnutrition and malabsorption seen commonly in the elderly may cause deficiency of vitamin B₁₂ and folic acid, both necessary for homocysteine metabolism, and lead to vascular damage. Altogether, these lead to brain damage in old age and greatly increase the risk of developing diseases of the central nervous system, such as stroke, epilepsy, Parkinson’s disease, Alzheimer’s disease, and other dementias.

Keywords: aging, molecular factor, neurological diseases

1. Introduction

Physiological aging starts after 60 years of age. Senescence in both animal models and humans is accompanied by alterations in the function of central cholinergic neurons. These changes essentially involve decreased levels of cholinergic receptors, reduced synthesis and release of acetylcholine, and a marked decrease in the number of muscarinic cholinergic neurons, all which may be linked to the age-related memory deficits, a typical change in
Alzheimer’s disease (AD) patients. Moreover, a decrease in the levels of dopaminergic neurons of up to 40–50% may be observed in the substantia nigra and of dopamine in the striatum at the end of the sixth decade of life, which are typical changes seen in patients with Parkinson’s disease (PD).

Increased longevity in much of the developed world appears to have lead to higher stroke incidence. Apart from an aging population, there is a significant impact of the growing prevalence of hypertension, diabetes, obesity, and disorders of the cardiovascular system on the increase in the incidence of stroke. The prevalence of these diseases increases with age.
The most common causes of epilepsy in the elderly are vascular changes in the brain (approximately 5%) and degenerative diseases of the central nervous system (CNS) (10–20%). Seizures also occur in patients with AD, demyelinating diseases (multiple sclerosis, or MS), metabolic disorders, as well as in toxic and hormonal disorders, or in individuals with a history of brain injuries or CNS infection.

The mechanisms leading to the development of neurological disorders in the elderly have not been fully elucidated. There are no known mechanisms that regulate cell death in the aging brain. It is not known whether the age of various cells induces the process of apoptosis and other mechanisms of neuronal death, and what factors determine the susceptibility to developing neurological diseases in old age. Understanding the causes of the increased incidence of neurological diseases in the elderly may help in their prevention and improve quality of life in old age (Figure 1).

The following review is based on literature search through public databases, such as PubMed and Scopus, with the use of keywords: “aging,” “molecular mechanism,” “neurological diseases,” “stroke,” “epilepsy,” “vascular dementia,” “Alzheimer’s disease,” “Parkinson’s disease,” and “brain tumor.” Subsequently, the authors selected eligible publications and performed further searches through their references in order to find additional articles. The last search was performed in February 2017.

2. The molecular mechanisms of aging

The molecular mechanisms of aging include genome instability as a consequence of the accumulation of gene mutations, telomere attrition, and epigenetic alterations. Interestingly, instability occurs more frequently in some genome regions than in others. The association and interactions between the above mechanisms lead to the functional decline of aging organisms.

2.1. Aging due to DNA damage

The theory of aging establishes that somatic mutations happen randomly during an organism’s lifetime and their accumulation eventually affects key functions such as DNA synthesis, degradation, and repair, consequently causing the “error catastrophe.” Genetic damage occurs both in nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) [1, 2]. However, mitochondria have an oxidative environment, due to multiple redox reactions in the electron transport chain, and a less efficient DNA repair system, which results in the accumulation of more damaged mDNA than nDNA [3, 4]. The decreased activity of autophagy and mitophagy may also be responsible for the accumulation of mtDNA mutations and mitochondrial dysfunction during aging [5].

The integrity and stability of DNA may be disrupted both by exogenous factors, such as physical, chemical or biological agents, as well as endogenous factors, including DNA replication errors and reactive oxygen species (ROS) [6]. Most of the damage to DNA occurs during the replication process, and the majority of this damage is corrected by a complex network of DNA repair mechanisms. The mismatch repair (MMR) system provides the fidelity
of replication. The checkpoint response is activated by damage that is unrepaired and leads to cell senescence or death, which may also alter tissue and the homeostasis of the body. The loss of key MMR proteins has been observed during aging. The question becomes: is such deterioration a cause or an effect of senescence [7, 8]?

The cell cycle and repair processes are controlled by tumor protein 53 (p53, encoded by TP53 gene), which is a pivotal regulator of multiple cellular processes, such as reversible and irreversible cell cycle arrest and senescence. The protein is activated by various stress factors to induce apoptosis or autophagic cell death, depending on the cell category [9]. The initiation of cellular aging is designed to prevent proliferation of damaged cells and tumorigenesis. Two main groups of signals activate p53: DNA damage and oncogenic stress. It has been demonstrated that loss of p53 function occurs in senescent cells, as 50% of human neoplasms possesses a mutated copy of the TP53 gene [10]. Moreover, the mutations in TP53 were observed also in age-related dementias, such as AD in both humans and its murine model [11, 12] (Figure 1).

2.2. The role of telomeres

Telomere attrition is another molecular mechanism responsible for senescence. Telomeres are a structural component of chromosomes localized at the end of each chromatid. They consist of DNA and telomere binding proteins. Telomere DNA is made up of the sequence 5’-TTAGGG-3’ repeated 150–2000 times [13]. The main functions of telomeres are protection against loss of genetic information during replication and prevention of abnormal recombination, chromosome fusion, or chromosomal degradation by exonucleases [14]. During each cell division, the telomere sequence is shortened by a length of 50–200 base pairs (bp) and the structure of telomeres changes. This biological clock is considered to be one of the main mechanisms determining the number of possible cell divisions. Hayflick’s observations [15] on somatic cells specified the maximum number of divisions after which cells stop dividing but remain metabolically active. This maximum number is called the Hayflick limit and varies by tissue type and organism. It is known that a reduction in the number of divisions prevents the accumulation of mutations [16].

2.3. Epigenetics of aging

Epigenetic alterations are another molecular mechanism involved in aging and include DNA methylation and histone modifications [17]. The epigenome becomes deregulated with age. Global levels of DNA methylation decrease with age, and changes in the methylation profile may lead to age-associated immune deficiency [18]. The chemical modification of histones includes acetylation, methylation, phosphorylation, ubiquitination, deamination, citrullination, sumoylation, ADP (adenosine diphosphate) ribosylation, and proline isomerization and lead to changes in histone-DNA or histone-histone interactions [19]. Both changes in the DNA methylation pattern and histone modifications can directly alter chromatin packaging, resulting in different parts of the DNA being exposed to transcriptional factors and results in the expression of different genes. Epigenetic studies have demonstrated progressive changes at the
transcriptomic level associated with aging. The age range of 49–56 years in humans seems to be critical in transcriptional senescence. Changes in gene expression, either their increase or decrease, are a longitudinal and dynamic process [20] (Figure 1).

2.4. Aging of the brain

Furthermore, senescence comprises aging of the cerebral white matter (WM) and gray matter (GM), including progressive neuronal loss, decreased levels of neurotransmitters, increased inflammation, disrupted integrity, lesions, infarction, and microbleeds [21]. Aging affects not only neurons but also glial cells (astrocytes, oligodendrocytes, microglia), vascular cells, and the basal lamina matrix and interferes with their functions such as maintaining metabolic and ion homeostasis in the CNS, regulating the cerebral blood flow, impulse conduction, and phagocytosis [22]. During aging, the reduction of WM volume is almost threefold higher (loss of 28% of neurons) than the reduction of GM volume (10% of neurons). Thus, changes in WM may result in behavioral and cognitive decline in the elderly. Additionally, the ability for WM repair has been found to be decreased in older individuals. Changes in WM are observed in diseases, such as stroke, PD, and AD [21].

Multiple molecular changes take place during aging, and these form a vast network of interactions. This makes it nearly impossible to determine if age-related diseases are caused by a snowball effect of senescence, or if the converse is true: that these diseases are the result of individual variability. It seems that both hypotheses may be true, as aging is an important risk factor for diseases such as stroke, epilepsy, PD, AD, and brain tumors, but not a certain causative factor (Figure 1).

3. Neurological diseases associated with aging

3.1. Stroke

According to World Health Organization (WHO), stroke is defined as “rapidly developing clinical signs of focal (or global) disturbance of cerebral function, lasting more than 24 hours or leading to death, with no apparent cause other than that of vascular origin” [23]. There are two main types of stroke, ischemic and hemorrhagic, which have different pathogenesis.

3.1.1. Ischemic and hemorrhagic stroke

In an ischemic stroke, the blood supply to some brain areas is reduced due to narrowing or complete occlusion of arteries, which leads to dysfunction of this part of the brain tissue. The molecular mechanisms involved in the pathomechanism of ischemic stroke include progressive damage of the blood-brain barrier (BBB) due to loss of integrity, degeneration or death of neurons, glial reaction, and infiltration of immune cells. Ischemic stroke represents 85–90% cases of stroke [24, 25]. Age-related changes in WM are thought to increase the risk for stroke, poststroke death [26], and ischemic injury after stroke [27]. One of the molecular features
of ischemic stroke in the elderly is excitotoxicity due to changes in protein expression (e.g. increase in GLT-1, a transporter for glutamate) and production of ROS. The generation of ROS leads to the death of oligodendrocytes and to the disruption of axons within WM. In the aged brain, the functional decline of mitochondria and antioxidant systems is associated with greater oxidative stress and worsen the WM injury upon ischemia [21].

Hemorrhagic stroke may be caused by cerebral hemorrhage and subarachnoid hemorrhage as a result of damage to the brain’s blood vessels by chronic hypertension, cerebral arteriovenous malformation, intracranial aneurysm, disambiguation, cerebral amyloid angiopathy, or drug-induced bleeding. The molecular basis of such a hemorrhage is represented by cytotoxicity of blood, hypermetabolism, excitotoxicity, oxidative stress, and inflammation [28, 29].

3.1.2. Senescence, civilization diseases, and stroke

The American Heart Association has reported that stroke is the fifth cause of death in the United States [30]. The risk factors of stroke are divided into modifiable (e.g. hypertension and other cardiovascular diseases, migraine, diabetes, dyslipidemia, diet, addictions) and unmodifiable (age, sex, race, genetic factors). Among the unmodifiable risk factors, the most important is age [31]. The risk of stroke increases exponentially with age in both men and women. It is estimated that the incidence of stroke doubles with each decade of life after the age of 55 and affects as many as 5% of people over the age of 65 [32]. It is known that the majority of modifiable risk factors, such as hypertension, atrial fibrillation, hyperhomocysteinemia (HHcy), and inflammatory processes (e.g. periodontal disease, infections, increased hs-CRP), are more common in the elderly. The effect of aging on the cardiovascular system is cumulative [33]. Atrial fibrillation occurs in 5% of individuals aged 70 or above and is a cause of one quarter of stroke incidents in patients at the age of 80. The risk of stroke can be decreased by antithrombotic therapies [34].

The serum total homocysteine (Hcy) concentration is another independent risk factor of ischemic stroke in the elderly, as it correlates with thrombosis. The population attributable risk of stroke incidence in high Hcy levels (>17.4 μmol/L) changes with age and was estimated at 21 and 26% for age 40–59 years (men and women, respectively) and at 35 and 37% for individuals over 60 years of age (men and women, respectively) [35]. HHcy (level of Hcy more than 15.0 μmol/L) promotes the development of atherosclerosis. Clinical studies have shown that HHcy has a toxic impact on both the vascular and nervous systems and may be observed not only in stroke but also in PD, mild cognitive impairment (MCI), and epilepsy [36]. Supplementation of folate and vitamin B\textsubscript{12} is essential in the treatment of HHcy, but folate alone does not reduce the risk of stroke [37].

Two thirds of the population aged over 65 years suffers from hypertension [31]. Hypertension has been proven to increase fourfold the risk of stroke; as the blood pressure increases, so does the probability of suffering stroke. Fortunately, a blood pressure reduction of about 10/5 mmHg decreases the risk of stroke by about 35% [33]. Hypertension is often linked with obesity, abnormalities in lipid profile, and type 2 diabetes. Together, these comorbidities contribute to atherosclerosis and thromboembolic stroke.
Diabetes has been found to have a greater impact in developing stroke in women than in men. Diabetes is a significant independent contributor of stroke in older women [38, 39]. However, the risk of stroke in diabetic patients can be decreased with proper intervention and treatment. The Systolic Hypertension in the Elderly Program has shown that antihypertensive treatment in individuals with diabetes can reduce the risk of stroke by about 20% [40].

Disturbances in the lipid profile should be regularly reviewed and treated as necessary, as they are another contributor to stroke. Independent studies have shown that high levels of total cholesterol (in the 240–270 mg/dL range) [41–43] and triglycerides [44, 45] as well as a low level of high-density lipoproteins (HDL, up to 35 mg/dL) [43, 46, 47] increase the incidence of ischemic stroke. According to the Heart Protection Study, statin therapy in the elderly group can reduce the risk of a first stroke by 29% [48]. Another side of the coin is obesity, defined as body mass index (BMI) >30 kg/m², or abdominal obesity, defined by a waist circumference >102 cm (men) and >88 cm (women) [33]. It is known that abdominal obesity is a stronger predictor of stroke than BMI [49].

Moreover, it has been observed that infection with some pathogens may cause acute stroke within a week; these pathogens are *Chlamydia pneumoniae, Haemophilus influenzae*, *Mycoplasma pneumoniae*, *Helicobacter pylori*, Cytomegalovirus, Epstein-Barr virus, and Herpes simplex virus types I and II. This occurs due to the activation of leukocytes and increased tendency for thrombosis at the site of atherosclerotic plaque. Because of immune deficiencies, the elderly are more susceptible to infections and, therefore, to postinfection complications [33].

It should be mentioned that controlling and regulating the modifiable risk factors is extremely important in stroke prevention. Older people tend to pay more attention to stroke avoidance. Epidemiological studies performed in the USA assumed that, in the last decade, the stroke death rate declined more in subjects after the age of 65 than in the younger population [30].

Stroke is a heterogeneous syndrome, with possible genetic background. Single-gene diseases may cause rare, hereditary disorders for which stroke may be a primary manifestation. Recent studies suggest that common and rare genetic polymorphisms that induce diabetes, hyperlipidemia, or hypertension may activate specific stroke mechanisms causing dangerous angiopathies [50]. For instance, the genetic variation at chromosome 16 (locus q24.2) had been shown to induce small vessel stroke. Traylor et al. using modern GWAS method have found that rare variant rs12445022 in *ZCCHC14* gene may induce small vessels dysfunction, thus greatly increase the risk of stroke [51]. Another interesting genetic factor studied in stroke is a polymorphism in *BDNF* gene (rs6265), which results in amino acid change (Val→Met) in the precursor protein, causing a reduction in brain-derived neurotrophic factor (BDNF) activity, which plays a role in rehabilitation after stroke. The studies show that concentrations of BDNF were decreased in acute ischemic-stroke patients compared to controls. BDNF signaling is dependent on the genetic variation which could affect an individual’s response to recovery after stroke. The rs6265 polymorphism may also affect the risk of ischemic stroke, post-stroke outcomes and the efficacy of the various forms of rehabilitation [52] (Figure 1).
3.2. Epilepsy

Epilepsy is one of the most common neurological diseases, with approximately 50 million sufferers worldwide. Epilepsy is a collection of somatic, vegetative, and/or mental symptoms, which may be the result of morphological or metabolic changes in the brain. Although the disease has a chronic character and had long been thought to be connected with events in infancy or childhood, epidemiological studies have revealed that there is pronounced incidence of epilepsy in people over 65 years of age [53, 54]. To date, many various causative factors have been associated with epilepsy. However, the etiology of the disease remains unknown in 65–75% of patients [55].

Epilepsy that develops after the age of 60 is symptomatic in the vast majority, although generalized epilepsy may also rarely manifest in the elderly [56]. Epileptic seizures are often under-diagnosed in that age group. The symptoms are usually recognized as memory disorders or mental changes of uncertain origin [57]. Risk factors for epilepsy and seizure etiology vary with age. The most common mechanism of pathogenesis of new-onset epilepsy and seizures in the elderly may be associated with cerebrovascular diseases (CVDs), neuron degenerative disorders, intracerebral tumors, and traumatic head injury [58, 59].

3.2.1. Epilepsy and cerebrovascular diseases

CVDs account for 30–50% of all identified causes of epilepsy in the elderly [60, 61]. Epilepsy attacks may be affected by a stroke and may occur immediately after an ischemic event or be delayed. Seizures may also be the first clinical manifestation of brain ischemia or hemorrhage, increasing the risk to develop epilepsy within the first year after the vascular episode by 20 times. The study of Alberti et al. [62] showed that hemorrhagic transformation of an ischemic stroke is a predictive factor for epilepsy and may also be related to the disruption of the BBB [63]. Numerous genetic factors may be engaged in epileptogenesis. According to Yang et al. [64], mitochondrial aldehyde dehydrogenase 2 (ALDH2, encoded by the ALDH2 gene) has a protective effect in CVDs. Nevertheless, allele A of the rs671 polymorphism in the ALDH2 gene was shown to be connected with post-stroke epilepsy due to decreased activity of ALDH2 leading to accumulation of the potential ALDH2 substrate—4-hydroxynonenal (4-HNE), considered to be a specific marker of oxidative stress and involved in myocardial and cerebral ischemia. Zhang et al. [65] suggest that the T allele of the -1C/T polymorphism in the CD40 gene may be associated with susceptibility to poststroke epilepsy (Figure 1). The proposed mechanism includes raised plasma concentrations of sCD40L, which is involved in the inflammatory response. Moreover, poststroke epileptogenesis was shown to be associated with lifestyle factors (alcohol use), acute metabolic disturbances (hyperglycemia), non-CNS comorbidities (type 1 or 2 diabetes, hypertension, coronary heart disease or myocardial infarction, as well as peripheral infections), CNS diseases (early seizures, depression or use of antidepressants, dementia), and pharmacotherapy (statins) [66].

3.2.2. Epilepsy due to head trauma

Another causative factor of epilepsy in the elderly may be head trauma. Due to an increased likelihood of imbalance, older people are more prone to falls causing head injuries. Acute events,
such as skull fractures, subdural hematoma, brain contusion, accidental injury, concussion, or loss of consciousness, were shown to be associated with increased risk of posttraumatic epilepsy [67]. Moreover, various genetic factors were shown to be associated with head injury as a risk factor for late posttraumatic seizures. Díaz-Arrastia et al. [68] showed that carriers of the pathogenic APOE E4 allele were more likely to develop epilepsy after suffering acute head trauma (Figure 1).

3.2.3. Epilepsy due to brain tumor

Epileptic seizures are common symptoms of brain tumors (BTs) in 20–40% of patients. The study of de Assis et al. [69] demonstrates that BTs related to epilepsy include primary CNS lymphoma, meningioma, anaplastic ependymoma, and anaplastic astrocytoma. The highest incidence of epilepsy occurs in low-grade tumors like primary astrocytoma, oligodendroglioma, mixed astrocytoma WHO grade I and II, as well as meningiomas. It seems that the incidence of seizures is inversely correlated to the grade of the malignancy. Age is a risk factor for increased mortality in those BT patients who develop seizures. Epilepsy attacks also appear in 67% of patients with melanocytic brain metastases, in 48% patients with lung cancer metastases, in 33% patients with breast cancer, and in 55% of patients in whom the primary cancer type was unknown. Unfortunately, BT-related epilepsy is characterized by pharmacological resistance [69, 70].

3.2.4. Biochemical factors in epilepsy

Hcy seems to have additional and interesting significance for the development of epilepsy. As stated earlier, HHcy has demonstrated an association with several disorders, including epilepsy [71]. High Hcy concentration has been shown to be related to numerous factors, including lifestyle (smoking, high consumption of alcohol, caffeine), age (due to the weakening of the excretory function of the kidneys, malabsorption of vitamin B12 in the stomach, hormonal disorders, e.g. in women during and after menopause), comorbid diseases, pharmacotherapy (e.g. antidiabetic drugs or fibrates), or unbalanced diet (deficiency of vitamin B12 or folic acid) [72–75]. Moreover, Schwaninger et al. [76] demonstrated that prolonged treatment with antiepileptic drugs (AEDs) may increase the plasma concentration of Hcy. On the other hand, the authors were not able to conclude whether the HHcy in epilepsy patients was a sole effect of pharmacotherapy or a causative factor of the disease.

Seizures may also occur in metabolic disorders, because of multiple comorbidities and polypharmacy. There should be a high index of suspicion for electrolyte imbalance, especially hyponatremia and hypoglycemia, in this group of patients. Other metabolic disorders, such as hyperglycemia and uremic or hepatic encephalopathy, are less specific to this age group [77]. The role of alcohol appears to be less important in the elderly than in young adults, but should not be neglected [78], as it may intensify the number of calcium channels and promote seizure activity by increasing the concentration of neurotransmitters [79].

3.2.5. Epilepsy in degenerative diseases

AD is a significant risk factor of epilepsy in the elderly. Imfeld et al. [80] suggested that patients with a longer history of AD (≥3 years) may have a higher risk of developing seizures
or epilepsy than those with a shorter duration of disease. Similar results were presented by Amatniek et al. [81], who observed that the incidence of seizures increased as the disease progressed; the cumulative incidence over 7 years was 8%. The risk of seizure onset is higher in AD patients with hyperlipidemia and severe dementia [82]. The epileptogenetic mechanism has not yet been elucidated in patients with neurodegeneration. It might be associated with β-amyloid (Aβ) deposition, neuronal loss and gliosis, and antidementia drugs [83, 84]. High levels of Aβ are considered a cause of AD, but they are also related to synaptic activity. Aβ serves as a potent regulator of synaptic transmission, causing presynaptic facilitation at relatively low Aβ concentrations and postsynaptic depression with higher Aβ levels. The modulation of synaptic transmission has an important effect on producing epileptiform activity [85].

Another degenerative disorder which may potentially induce seizures is MS, a chronic disease of the CNS. MS usually occurs in young adults (aged 20 to 40 years). However, 1.1–12% of MS patients experience the first symptoms of the disease after the age of 50 [86]. The prevalence of seizures among MS patients was shown to be higher than the general population, which may indicate the relationship between seizures and MS [87]. One possible explanation is that MS lesions act as epileptogenic sites [88]. Generally, a small fraction (2.5%) of MS patients develop seizures [89]. The study of epilepsy in the elderly among MS patients is inconclusive, but clinicians should be aware of the risk of epilepsy in people with MS [88].

### 3.3. Aging and dementia

Dementia—as a form of cognitive decline—is strongly associated with old age. Almost 10% of those older than 65 years suffer from some kind of memory impairment. The most common causes of dementia include AD and vascular dementia (VaD). The prevalence of dementia increases with age, affecting nearly 50% of the population over 85 years of age. Dementia is a progressive disorder, finally leading to severe disability and complete dependence of sufferers on caregivers [90].

#### 3.3.1. Vascular dementia

VaD was initially understood to be an advanced effect of repetitive brain lesions [91]. The development of brain imaging techniques revealed that silent ischemic lesions appeared to be quite common and later became known as a significant cause of dementia [92, 93]. Epidemiological studies have shown that vascular dysfunction causes 10–20% dementia cases [94, 95]. The frequency of VaD in the general population varies from 1.2 to 4.2% of individuals over 65 years, depending on the methodological approach [94, 96]. The prevalence of VaD is strongly connected with age. A Canadian study described that frequency of vascular cognitive impairment increased from 2.0% in those aged 65 to 74 years to 13.7% in those over 85 years of age [97]. A meta-analysis from 1998, synthesizing the results of 23 studies from around the world, confirmed the trend of increasing incidence of VaD in senescence [98]. Increasing longevity in many populations has also increased the importance and burden of vascular-related memory deficits. A long-term survey demonstrated that the incidence of post-stroke dementia between 1984 and 2001 had doubled [99].
Several studies have analyzed the risk factors, other than age, of CNS vascular lesions. They identified hypertension, heart disease, diabetes with insulin resistance, and dyslipidemia to be related to an increased risk to develop VaD. It is important to note that the results obtained by different authors occasionally contradict each other [100–109]. The cluster of cardiovascular risk factors, also called “metabolic syndrome,” that include dyslipidemia, obesity, hypertension, and insulin resistance, has also been shown to be associated with VaD [110, 111]. Additionally, patients with fully symptomatic metabolic syndrome obtained lesser scores in neuropsychological testing [112]. Moreover, HHcy, previously associated with vascular diseases and stroke, was shown to be associated with VaD [113].

Many studies have also demonstrated that a symptomatic stroke incident, occurring mostly in the elderly, may inflict memory deficits in 6 to 32% of patients, depending on the follow-up period (3 months—20 years) [114–128]. MCI preceding stroke increases the probability of post-stroke dementia [129, 130], and memory decline seemed to progress more rapidly with later stroke episodes [131]. Similarly, recurrent stroke was associated with greater cognitive impairment when compared with patients with a single vascular incident [122] (Figure 1).

3.3.2. Alzheimer’s disease

AD is the most common form of dementia in older adults [132]. AD is a progressive incurable neurodegenerative disease where aging is the primary risk factor. AD may be divided into two main clinical subtypes: familial AD (FAD) characterized by early onset (before 65 years of age) and, frequently, the presence of mutations in the APP, PSEN1, and PSEN2 genes. This genetic triad is responsible for nearly half of the FAD cases seen [133]. However, mutations in these genes occur very rarely in the human population. Subsequently, the majority (90%) of AD cases are sporadic (SAD) and manifest mostly in patients over 65 years of age. The multifactorial character of the disease makes it extremely difficult to determine a causative factor for SAD [134]. To date, nearly 700 genes have been associated with AD, although the most investigated risk factor for SAD remains the E4 allele of the APOE gene [90, 135, 136].

The diagnosis of probable AD is based on clinical criteria [137], however, the disease may be diagnosed with certainty only after death, by histopathologic study of the brain, revealing characteristic lesions: Aβ plaques and neurofibrillary tangles (NFTs) formed by hyperphosphorylated protein tau. Aβ is formed via pathologic cleavage of (amyloid precursor protein (APP), encoded by the APP gene) by β- and γ-secretases (encoded by the BACE and PSEN genes, respectively). The appearance of Aβ plaques and NFTs seems to be one of the causes for neurodegeneration: the morphological and functional loss of neurons and synapses, as well as excessive neuroinflammatory processes occurring in AD brains. Martin et al. [138] showed that aging and Aβ pathology may activate similar receptors on microglia and monocyte-derived macrophages. Moreover, carriers of the APOE E4 allele and rare variants in other genes, such as HLA-DRB5/DRB1, INPP5D, MEF2C, CR1, CLU, and TREM2, may exhibit an even stronger activation of microglia than noncarriers [139]. This explains why older patients with unfavorable genetic variants are more prone to excessive neuroinflammatory responses leading to neuronal loss and dementia.
The neurons mostly affected by AD are cells expressing acetylcholine (ACh) receptors, also called “cholinergic neurons” (AChN). Loss and degeneration of this type of cells is another hallmark of dementia and occurs gradually with age and the course of the disease [140]. The age-related degeneration of AChN leads to decreasing levels of ACh in the brain. ACh has been proven to be the neurotransmitter that is most reduced in the majority of AD patients [141]. It seems that genetic factors, such as the presence of the pathogenic APOE E4 allele, may also significantly influence the production and release of ACh. The study on transgenic mice expressing human APOE indicated that age-related decrease in ACh levels released by the hippocampus was more prominent in mice with human APOE E4/E4 than in mice with APOE E3/E3 variants [142] (Figure 1).

The main cholinergic structure of the brain is the basal forebrain (BF), the underlying neurodegeneration of which may be observed in advanced aging as well as in the early phase of AD and other dementias [143]. BF degeneration occurs due to a decrease in cholinergic neurotransmission and a reduction in the amount of ACh in synaptic clefts, followed by a loss of cholinergic receptors, finally resulting in AChN death. This process, according to the “cholinergic deficit hypothesis,” results in behavioral and cognitive impairment, especially learning difficulties, which advance rapidly with age [144].

It is worth noting that in AD, similarly to VaD and stroke, the concentration of Hcy may be increased and so may inflict damage to the vasculature, thereby leading to decreased blood flow and inefficient nutrient delivery to neurons. Subsequently, the starving cells become more prone to ROS and apoptosis. HHcy is also associated with a decrease of the glutathione pool, the deficiency of which results in the deterioration of protection mechanisms from free radicals, further contributing to neuronal loss and neurodegeneration [145].

3.4. Parkinson’s disease and aging

PD is an age-related neurodegenerative disease characterized by resting tremor, rigidity, and bradykinesia. The number of PD patients increases over the years due to population aging. The exact pathomechanism of PD remains unclear, but it is known that the degeneration process starts many years before the occurrence of clinical symptoms. The hallmark of PD is dopaminergic (DA) neuron death in the substantia nigra (SN), which is a result of Lewy body (LB) formation due to impairment of the ubiquitin-proteasome system and disturbances in the proteins alpha-synuclein (ASN) and Parkin [146, 147]. Molecular characteristic of PD include increased ROS production due to mitochondrial dysfunction and accompanied by decreased mitophagy [148], neuroinflammation and loss of neurotrophic factors [149, 150], exposure to (1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)) or paraquat [151], exposure to trichloroethylene or polychlorinated biphenyls [152], iron (the level of which increase in the SN with age), copper, manganese [153, 154], or mutations in PARK genes [155]. Mitochondrial dysfunction is associated with aggregation of ASN, apoptosis, accumulation of damaged mitochondria, and changes in the activity of complex 1 [156]. A decline in mitochondrial function as well as inflammation and changes in DA metabolism are linked with the aging process.
Advancing age is the most important risk factor of developing PD. PD affects about 1% of the population over the age of 60 and 5% over the age of 85 [157]. It has been since 1987 that the loss of DA neurons progresses with aging, but the rate of the physiological process is slower than that seen in PD [158]. Moreover, LB may be present in elderly individuals without PD [159]. The aging brain is also more prone to stressor stimuli and generation of ROS, which results in the injury and eventual death of SN neurons. On the other hand, a decreased level or even loss of ROS scavengers, e.g. neuromelanin, in the PD brain may be a cause of DA neuron damage rather than an effect of this damage [157].

Many epigenetic mechanisms, such as changes in DNA methylation profile and histone modification, play an important role in aging and contribute to PD. The epigenetic clock can be characterized just by measuring the DNA methylation pattern. Interestingly, PD patients represent an increased acceleration in aging when compared to controls of the same age [160]. Hypomethylation of SNCA, the gene encoding ASN, leads to an increased expression of ASN and has been observed in the SN of PD patients [161]. ASN can also influence histone acetylation (a feature of transcriptionally active genes) and enhance ASN fibrillation [162].

During normal aging, the functional decline of the BBB can cause neuroinflammation and the development of neurodegenerative diseases [163]. Disturbances in BBB permeability observed in the senescence process may be involved in the genesis of WM lesions, which may also affect the efficacy of treatment. In the course of aggregation of ASN in PD, elevated ROS production and increased levels of proinflammatory cytokines or toxic agents may intensify disruptions of the BBB [164].

HHcy observed in PD may be involved in the disease pathogenesis; however, the exact mechanism of interaction remains unrecognized. Both HHcy and age are risk factors for developing dementia in PD patients [165]. Treatment with L-dopa may be responsible for HHcy in individuals with PD [166]. In those patients, Hcy is formed in the methylation of L-dopa via catechol-O-methyltransferase (COMT) [167]. Other side effects of L-dopa at the molecular level include increased oxidative stress, as well as altered concentrations of catecholamines and apoptotic proteins [147]. Damage of DA neurons due to oxidative stress may be enhanced by elevated Hcy (Figure 1). A study performed on mice has shown that elevated Hcy increases the sensitivity to MPTP and developing PD-like dysfunction [168].

3.5. Brain tumors in the elderly

Another type of CNS disease, manifesting particularly in the elderly, are brain tumors, classified according to WHO criteria to four grades, with grade IV considered most malignant [169]. In adults, the most prevalent type of primary brain tumor is malignant glioma (MGs), with the highest incidence between 40 and 65 years of age. The majority of MGs are sporadic, with ionizing radiation as the only known risk factor. The most common type of glioma is glioblastoma multiforme (GBM), qualified as a WHO grade IV astrocytic tumor, and constituting about half of all MGs with the highest incidence in the elderly, between 70 and 90 years of age [170–172]. Old age is a negative prognostic factor in GBM [173]. One of the most significant characteristics of GBM is an increasing prevalence with age; thus, due to an increasing median
GBMs comprise a rather heterogenic group of neoplasms, with two major types: primary glioblastomas (85–90%) and secondary GBMs that arise from low-grade astrocytomas (10–15%) [175]. Although both types are indistinguishable under the microscope, they appear to differ genetically. Genetically, primary GBMs exhibit by amplification and mutation of the \( EGFR \) gene, a lack of heterozygosity on chromosome 10q, inactivation of the \( PTEN \) homolog gene, and only rare occurrence of mutations in the \( IDH \) and \( TP53 \) genes. Conversely, the genetics of secondary GBM are characterized by mutations in the \( IDH \) and/or \( TP53 \) genes, as well as platelet-derived growth factor receptor activation [176]. A gene expression-based GBM classification was established by The Cancer Genome Atlas (TCGA) Research Network in 2010. The authors distinguished four subtypes of GBM. Characteristics that differentiate the subtypes at most were indicated as follows: proneural GBM has alterations of the \( PDGFRA \) gene and point mutations of \( IDH1 \), classical GBM has \( EGFR \) aberrations, and mesenchymal demonstrates GBM aberrations in \( NF1 \). The fourth subtype, neural GBM, is characterized by the expression of neuron markers such as \( NEFL \), \( GABRA1 \), \( SYT1 \), and \( SLC12A5 \). Each subtype of GBM differs in its sensitivity to radiotherapy and chemotherapy, thus determining the genetic type of a surgically removed or biopsied lesion could protect patients against unnecessary ineffective therapy [177].

Unfortunately, GBMs are mostly incurable in the elderly, with most of these patients surviving less than 6 months [171]. Diagnosis of primary brain tumors in old age can be further complicated and delayed due to nonspecific symptoms that can be masked by physical and cognitive changes observed in the normal aging process [178]. Moreover, elderly patients are an underrepresented group in many clinical trials [179]. The literature data indicate that, at the close of the twentieth century, the chances of receiving a treatment, be that surgery and/or radiotherapy, were decreasing as the patient got older. Treatment mostly took place for 82% of patients younger than 65 years of age, whereas only 47% of people older than 65 years and merely 25% of patients older than 75 were subjected to any kind of therapy. Additionally, patients treated with radiotherapy and/or surgery had a significantly lower survival rate as they crossed the age border of 60 years [180].

Although pathological processes differ depending on the glioma subtype, there is a common core of molecular events. Growth factor receptor tyrosine kinases cause downstream signaling by activation of extracellular signal-regulated kinases (ERK) or protein kinase B (Akt) pathways. Lack of p53 activation is followed by the loss of the ability to activate DNA repair processes and cell death by apoptosis. An additional adverse characteristic occurring in GBM is that the cells provoke the secretion of vascular endothelial growth factor (VEGF), which is responsible for angiogenesis. The secretion of VEGF by GBM results in vascularization of the tumor, elevation of capillary permeability of the BBB, and creation of extracellular edema [181]. Finally, due to vasculature growth, there is progression of tumor invasion [182].

Although these brain tumors are very invasive, it is important to note that, depending on the tumor subtype, they may be effectively treated in elderly patients by maximally safe surgical resection, radiotherapy, and/or chemotherapy with Temozolomide, a drug which is especially
preferable as first-line treatment in patients with the MGMT promoter [179, 183]. In addition to radiotherapy and/or Temozolomide, Bevacizumab (BV, Avastin®) is being studied for the treatment of brain tumors. BV is a humanized IgG1 monoclonal antibody targeting VEGF with high affinity and inactivating the growth factor. Thus, BV promotes tumor regression and helps to decrease the risk of cerebral edema [184]. Interestingly, it has been demonstrated that, although old age is a negative prognostic factor, BV was more effective in older patients (≥55 years of age); those treated with BV remained in better health longer and used lower doses of steroids. These findings were in line with the study published by Nghiemphu et al. [185], who demonstrated that expression of VEGF was 1.4-fold higher in older patients than in younger subjects, and so inhibition of VEGF could give a more positive outcome in these patients.

The increased incidence of brain tumors in the elderly may also be due to decreased efficiency of repair mechanisms. Inactivation of genes involved in DNA repair, such as the above-mentioned TP53 and MGMT, may advance with age. This may lead to increased accumulation of DNA damage, in turn resulting in further activation of proto-oncogenes and silencing of tumor suppressor genes. Such changes, inflicted either by mutation or epigenetic changes, may cause additional destabilization of cellular repair mechanisms, increasing the susceptibility to ROS and spontaneous mutagenesis, and triggering the positive feedback loop of neoplasia [186] (Figure 1).

4. Summary

The molecular mechanism of aging includes genome-wide changes such as genomic instability due to accumulation of mutations, telomere attrition, and epigenetic alterations. These changes collect over the years during the life of the organism, leading gradually to morphological and functional deterioration. The brain seems to be particularly vulnerable, as neurons generally do not divide and their pool decreases with the passage of time. Structural changes in the senescent brain affect mostly the cerebral WM and GM; these effects include progressive neuronal loss, decreased levels of neurotransmitters, increased inflammatory processes, and disrupted integrity of vessels and the BBB followed by infarction and microbleeds. These changes may lead to degenerative diseases, such as PD and dementias.

The frequently observed malnutrition and malabsorption syndrome in the elderly may cause decreased concentrations of the vitamins necessary for Hcy metabolism. This in turn results in increased injury to the cerebral vasculature, leading to degeneration and strokes. Consequently, progressive age-related vascular damage of the brain develops, additionally connected to an increased prevalence of epilepsy in the elderly.

An increased incidence of brain tumors may also be observed in old age, probably as an effect of the diminished efficiency of repair mechanisms. The inactivation of genes involved in DNA repair has been shown to advance with age. Such alterations, inflicted either by epigenetic changes or mutation, may cause further destabilization of immunologic systems and cellular repair mechanisms, thus increasing the susceptibility to ROS and spontaneous mutagenesis and resulting in uncontrolled cellular growth and age-related neoplasia (Figure 2).
Figure 2. Changes during the senescence process may be associated with neurological diseases. The pathological changes starting at the molecular level affect cells of the aging organism and lead to systemic deterioration, giving rise to age-related neurological diseases. ROS—reactive oxygen species, WM—white matter of the brain, and GM—gray matter of the brain.

In summary, the senescence mechanisms start at a molecular level and gradually lead to morphological disintegration and functional loss of brain cells. Finally, they lead to the deterioration of the CNS and an increased risk of developing neurological diseases.

Acknowledgements

This work was supported by the Poznan University of Medical Sciences grant no. 502-01-11111-45-07-467.
Author details

Marta Kowalska1, Michal Owecki1,2, Michal Prendecki1, Katarzyna Wize1, Joanna Nowakowska1, Wojciech Kozubski2, Margarita Lianeri1 and Jolanta Dorszewska1*

*Address all correspondence to: dorszewskaj@yahoo.com

1 Laboratory of Neurobiology, Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland
2 Chair and Department of History of Medical Sciences, Poznan University of Medical Sciences, Poznan, Poland
3 Chair and Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland

References


Primary prevention of ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006;113:e873-e923. DOI: 10.1161/01.STR.0000223048.70103.F1


[55] Jędrzejczak J. Epilepsy. The hardest are the answers to simple questions. Termedia, Poznań; 2008; 6-11. Book In Polish


Martinez-Lage J, Soininen H, Hofman A. Incidence of dementia and major subtypes in 
Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the 

14:240-257

and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment 


[99] Ukrain'tseva S, Sloan F, Arbeev K, Yashin A. Increasing rates of dementia at time 
of declining mortality from stroke. Stroke. 2006;37:1155-1159. DOI: 10.1161/01. 
STR.0000217971.88034.e9

tia: Incidence and risk factors in the Canadian study of health and aging. Stroke. 
2000;31:1487-1493. DOI: 10.1161/01.STR.31.7.1487

JC, Fitzpatrick A, Dubler C. Determinants of vascular dementia in the Cardiovascular 

[102] Suryadevara V, Storey SG, Aronow WS, Ahn C. Association of abnormal serum lipids 
in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic 
vascular disease without dementia, dementia without atherosclerotic vascular disease, 
and no dementia or atherosclerotic vascular disease. The Journals of Gerontology. 
Series A, Biological Sciences and Medical Sciences. 2003;58:M859-M861

[103] Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer 
archneur.61.5.705

of hypertension in the elderly to AD, vascular dementia, and cognitive function. 
Neurology. 2002;58:1175-1181

[105] Ross GW, Petrovitch H, White LR, Masaki KH, Li CY, Curb JD, Yano K, Rodriguez BL, 
Foley DJ, Blanchette PL, Havlik R. Characterization of risk factors for vascular demen 


[107] Geroldi C, Frisoni GB, Paolisso G, Bandinelli S, Lamponi M, Abbatecola AM, Zanetti 
O, Guralnik JM, Ferrucci L. Insulin resistance in cognitive impairment: the InCHIANTI 


[115] Desmond DW, Moroney JT, Sano M, Stern Y. Incidence of dementia after ischemic stroke: Results of a longitudinal study. Stroke. 2002;33:2254-2260. DOI: 10.1161/01.STR.000008235.91778.95


http://www.alzgene.org/- date of access 02.03.2017


Zhang ZG, Li Y, Ng CT, Song YQ. Inflammation in Alzheimer’s disease and molecular genetics: Recent update. Archivum Immunologiae et Therapiae Experimentalis. 2015;63:333-344. DOI: 10.1007/s00005-015-0351-0


Rampling R, Erridge S. Management of Central Nervous System Tumours in the elderly. Clinical Oncology (Royal College of Radiologists (Great Britain)). 2014;26:431-437. DOI: 10.1016/j.clon.2014.03.009


Flowers A. Brain tumors in the older person. Cancer Control: Journal of the Moffitt Cancer Center. 2000;7:523-538


Cohen AL, Colman H. Glioma biology and molecular markers. Cancer Treatment and Research. 2015;163:15-30. DOI: 10.1007/978-3-319-12048-5_2


